Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin-Reference-Cited by-同舟云学术

Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin

Published:2021-07-06 Issue:7 Volume:28 Page:
ISSN:1195-1982
Container-title:Journal of Travel Medicine
language:en
Short-container-title:

Author:

Yadav Pragya D¹,Sapkal Gajanan N¹,Ella Raches²,Sahay Rima R¹,Nyayanit Dimpal A¹,Patil Deepak Y¹,Deshpande Gururaj¹,Shete Anita M¹,Gupta Nivedita³,Mohan V Krishna²,Abraham Priya¹,Panda Samiran³,Bhargava Balram³

Affiliation:

1. Indian Council of Medical Research-National Institute of Virology, Pune, India

2. Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana, India

3. Indian Council of Medical Research, V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi, India

Abstract

SARS-CoV-2 variant of concern mainly Delta and Beta is global public health concern due to its impact on existing vaccines. Here, we assessed the neutralization of sera from COVID-19 recovered cases and BBV152 vaccinees against Beta and Delta variants. BBV152 vaccine found to confer significant protection against both the variants.

Funder

Indian Council of Medical Research

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

http://academic.oup.com/jtm/advance-article-pdf/doi/10.1093/jtm/taab104/39457576/taab104.pdf

Reference7 articles.

1. New SARS-CoV-2 variants—clinical, public health, and vaccine implications;Abdool Karim;N Engl J Med,2021

2. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals

3. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2;Sapkal;J Travel Med,2021